Subcutaneous administration of the drug had impressive clinical response in multiple myeloma.

Treatment with the bispecific antibody talquetamab resulted in a clinical response in a substantial percentage of patients with triple-class-refractory or relapsed multiple myeloma. This drug can be administered subcutaneously; thus, the delays and treatment burden associated with the...